X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (152) 152
index medicus (149) 149
hematology (95) 95
female (85) 85
male (77) 77
middle aged (75) 75
aged (64) 64
adult (58) 58
oncology (50) 50
leukemia, lymphocytic, chronic, b-cell - genetics (39) 39
prognosis (38) 38
abridged index medicus (36) 36
aged, 80 and over (31) 31
treatment outcome (25) 25
leukemia, lymphocytic, chronic, b-cell - pathology (23) 23
chronic lymphocytic leukemia (21) 21
cancer (20) 20
mutation (18) 18
survival (18) 18
therapy (17) 17
disease progression (16) 16
leukemia, lymphocytic, chronic, b-cell - drug therapy (16) 16
cll (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
expression (14) 14
herpesvirus 6, human - genetics (14) 14
leukemia (14) 14
leukemia, lymphocytic, chronic, b-cell - mortality (14) 14
lymphoma (14) 14
lymphomas (14) 14
molecular sequence data (14) 14
diagnosis (13) 13
infectious diseases (13) 13
microenvironment (13) 13
polymerase chain reaction (13) 13
risk factors (13) 13
base sequence (12) 12
care and treatment (12) 12
dna, viral - analysis (12) 12
hemic and lymphatic diseases (12) 12
ibrutinib (12) 12
infection (12) 12
leukemia, lymphocytic, chronic, b-cell - diagnosis (12) 12
polymerase chain-reaction (12) 12
adolescent (11) 11
analysis (11) 11
cd38 expression (11) 11
chronic lymphocytic leukaemia (11) 11
follow-up studies (11) 11
gene expression profiling (11) 11
identification (11) 11
leukemia, lymphocytic, chronic, b-cell - metabolism (11) 11
survival analysis (11) 11
bone marrow (10) 10
chronic lymphatic leukemia (10) 10
chronic lymphocytic-leukemia (10) 10
cohort studies (10) 10
hematology, oncology and palliative medicine (10) 10
immunoglobulin heavy chains - genetics (10) 10
immunoglobulin variable region - genetics (10) 10
immunology (10) 10
lenalidomide (10) 10
rituximab (10) 10
antineoplastic agents - therapeutic use (9) 9
dna (9) 9
health aspects (9) 9
hhv-6 (9) 9
review (9) 9
virology (9) 9
young adult (9) 9
aids/hiv (8) 8
cells (8) 8
chemotherapy (8) 8
genetics & heredity (8) 8
herpesvirus 6, human - isolation & purification (8) 8
infections (8) 8
internal medicine (8) 8
medicine (8) 8
multiple-myeloma (8) 8
peripheral-blood (8) 8
research (8) 8
retrospective studies (8) 8
studies (8) 8
activation (7) 7
acute lymphoblastic-leukemia (7) 7
association (7) 7
b-cells (7) 7
bortezomib (7) 7
chromosome aberrations (7) 7
dna mutational analysis (7) 7
fludarabine (7) 7
gene-expression (7) 7
genomic aberrations (7) 7
immunoglobulins (7) 7
in-vivo (7) 7
leukemia, lymphocytic, chronic, b-cell - immunology (7) 7
medicine & public health (7) 7
medicine, research & experimental (7) 7
multiple myeloma - drug therapy (7) 7
pathology (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 03/2014, Volume 32, Issue 7, pp. 634 - 640
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 986 - 993
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label,... 
LOW-DOSE WARFARIN | DEXAMETHASONE | THERAPY | VENOUS THROMBOEMBOLISM | ONCOLOGY | DEEP-VEIN THROMBOSIS | PREDNISONE PLUS THALIDOMIDE | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Warfarin - adverse effects | Male | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Multiple Myeloma - drug therapy | Thromboembolism - prevention & control | Time Factors | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Cardiovascular Diseases - mortality | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Risk Assessment | Multiple Myeloma - complications | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Thromboembolism - etiology | Thromboembolism - mortality | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Hemorrhage - chemically induced | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 02/2013, Volume 121, Issue 8, pp. 1403 - 1412
Journal Article
Haematologica, ISSN 0390-6078, 06/2013, Volume 98, Issue 6, pp. 980 - 987
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2013, Volume 8, Issue 12, pp. e83830 - e83830
CLL cell trafficking between blood and tissue compartments is an integral part of the disease process. Idelalisib, a phosphoinositide 3-kinase delta (PI3K... 
B-CELLS | SURVIVAL | MIGRATION | APOPTOSIS | CAL-101 | MICROENVIRONMENT | MULTIDISCIPLINARY SCIENCES | MOLECULE-1 | TYROSINE KINASE INHIBITOR | RECEPTOR | EXPRESSION | Cell Survival - drug effects | Integrin alpha4beta1 - metabolism | Purines - pharmacology | Stromal Cells - pathology | Bone Marrow Cells - pathology | Enzyme Inhibitors - pharmacology | Cell Adhesion - drug effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Integrins - metabolism | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Animals | Signal Transduction - drug effects | Stromal Cells - drug effects | Cell Line, Tumor | Mice | Gene Expression Regulation, Neoplastic - drug effects | Endothelial Cells - pathology | Vascular Cell Adhesion Molecule-1 - metabolism | Quinazolinones - pharmacology | Endothelial Cells - drug effects | B cells | Analysis | Integrins | Endothelium | Cell culture | Vascular cell adhesion molecule 1 | Phosphorylation | Pathogenesis | Leukemia | Shear flow | Trafficking | AKT protein | Kinases | Tissues | VLA-4 antigen | Blood | Lymph nodes | Cell adhesion & migration | Atrophy | Cell growth | Immunology | Lymphocytes | Compartments | Cell adhesion | Bone marrow | Inhibition | Antigens | Chronic lymphatic leukemia | CD49d antigen | Hematology | Internal medicine | Shrinkage | Lymphatic leukemia | Tumor necrosis factor-α | Adhesion | 1-Phosphatidylinositol 3-kinase | Inhibitors | Stromal cells | Lymphomas | Lymphocytosis | Binding sites | Chemokines | Apoptosis | Cancer | Index Medicus
Journal Article
Journal Article
Journal Article
Journal of Experimental Medicine, ISSN 0022-1007, 07/2011, Volume 208, Issue 7, pp. 1389 - 1401
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2014, Volume 9, Issue 6, pp. e98818 - e98818
The endothelin axis, comprising endothelins (ET-1, ET-2 and ET-3) and their receptors (ETAR and ETBR), has emerged as relevant player in tumor growth and... 
ACTIVATION | PROGNOSTIC-FACTOR | MICROENVIRONMENT | INDUCED APOPTOSIS | COLORECTAL-CANCER | MULTIDISCIPLINARY SCIENCES | PROLIFERATION | MACITENTAN | IDENTIFICATION | SUBTYPE-B | PACLITAXEL | Endothelin A Receptor Antagonists - pharmacology | Cell Survival - drug effects | Gene Expression | Cell Proliferation | Prognosis | Endothelin-1 - genetics | Endothelin-1 - metabolism | Humans | Cell Survival - genetics | Treatment Outcome | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Receptors, Antigen, B-Cell - metabolism | Receptor, Endothelin A - genetics | Endothelin-1 - blood | Drug Resistance, Neoplasm - genetics | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Receptor, Endothelin A - metabolism | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis | Cell proliferation | Phosphorylation | Peptides | Leukemia | Colorectal cancer | Chemoresistance | Cytotoxicity | Metastasis | B-cell receptor | Drug resistance | Kinases | Metastases | Ovarian cancer | Proteins | Angiogenesis | Receptors | Cell activation | Inhibition | Antigens | Chronic lymphatic leukemia | Cell survival | Hematology | Extracellular signal-regulated kinase | Endothelin 3 | MAP kinase | Endothelin 2 | Endothelin 1 | Lymphatic leukemia | Survival | Signaling | Hospitals | Inhibitors | Fludarabine | Lymphocytes B | Protein kinase | Plasma levels | Apoptosis | Index Medicus
Journal Article